1410 (1410) Fair Value & Analysis

Technology · Market cap HK$813M

1 1410 1410 · HK

PriceHK$0.8200

Fair ValueHK$0.3800

Upside-53.7%

Quality64/100

Evidence: High Range HK$0.2800 – HK$0.4700

Fair value as of: Jul 2, 2026

From 24 valuation models · updated today

Price vs Fair Value (12 months)

12‑month range HK$0.2030 – HK$0.8900 · fair‑value band HK$0.2800 – HK$0.4700 · the HK$0.8200 price screens above the HK$0.3800 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

1410 (1410) currently trades at HK$0.8200, while our model-based Fair Value estimate is HK$0.3800 — implying the stock looks roughly 53.7% overvalued today. We read business quality at 64/100 (solid quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, 1410 generated revenue of HK$777M at a net margin of 2.9%. Revenue grew 3.5% year over year. It earns a return on equity of 11.4%. The balance sheet holds a net cash position of HK$72.8M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Revenue (TTM) HK$777M

Revenue growth (YoY) +3.5%

Net margin 2.9%

Return on equity 11.4%

Free cash flow HK$65.6M FY2025

P/E ratio 40.5

More key figures

Operating margin -0.1%

EPS (TTM) HK$0.0600

EPS growth (YoY) -28.4%

Net cash HK$72.8M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

1410 reported revenue of HK$777M in FY2026 versus HK$525M in FY2022, a compound +10.3%/yr. Reported net income was HK$22.4M in FY2026, compounding −0.4%/yr from FY2022.

Revenue +10.3%/yr

FY22 HK$525M

FY23 HK$577M

FY24 HK$625M

FY25 HK$734M

FY26 HK$777M

Net income −0.4%/yr

FY22 HK$22.8M

FY23 −HK$27.5M

FY24 HK$29.7M

FY25 HK$24.5M

FY26 HK$22.4M

Is 1410 fairly valued? → Check now

Similar stocks

6 more Software - Infrastructure stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Microsoft Corporation MSF	€324.60	€273.67	-16%
MSFT MSFT	7,019 MXN	3,725 MXN	-47%
Oracle Corporation ORCL	$175.07	$68.15	-61%
Palantir Technologies Inc PTX	€107.36	€20.73	-81%
Palo Alto Networks, Inc 5AP	€227.65	€26.66	-88%
CrowdStrike Holdings CRWD	C$53.33	C$13.16	-75%

Explore undervalued stocks

More undervalued Technology stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 1410 (1410) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.3800 versus a price of HK$0.8200 — about −54% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 1410?

Our model-based fair value for 1410 is HK$0.3800 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$0.8200.

What is the quality score of 1410?

1410 has a Quality Score of 64/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 1410 (1410)?

1410 reported trailing-twelve-month revenue of about HK$777M (latest available figure, as of Jul 2, 2026).

What is the net profit margin of 1410?

The net profit margin of 1410 is about 2.9%, meaning it keeps roughly 2.9% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.